

# Comparative Study on the Efficacy of Injectable Platelet Rich Fibrin (i-PRF) and Albumin Gel (ALB-Gel) in Facial Rejuvenation: A Clinical Ultrasonographic Evaluation

## ABSTRACT

**Abstract:** Cutaneous ageing is a natural process associated with advancing age, potentially resulting in negative consequences on individuals' self-esteem. The primary manifestations of this process are the emergence of wrinkles, spots, dehydration, sagging, and loss of tissue vitality. In recent years, there has been a significant increase in the pursuit of more natural treatments for facial rejuvenation. In this context, using ALB-Gel and i-PRF stands out as a biological and autologous material. **Materials and Methods:** The measurement of the dermis using a 16 MHz ultrasound device and photographic documentation allowed for evaluating the technique's efficacy in reducing signs of ageing and nasolabial fold depth. The clinical study was conducted with 13 female participants aged 35 to 55 who underwent a session of ALB-Gel and i-PRF application in the right hemiface nasolabial fold region and i-PRF in the left hemiface. A paired t-test with a significance level of 5% was used in the statistical analysis. The scores on the Self-Perception Index were also statistically assessed using the Wilcoxon test at 5% to verify significant improvement. Additionally, new frontal and profile D and E photos were taken and compared with the initial images. **Results:** For the right hemiface nasolabial fold, a  $P < 0.0074$  was observed to compare initial and final signs; for the left hemiface, a  $P < 0.1259$  was obtained. These statistical results evidence a significant increase in dermal thickness in the right hemiface nasolabial fold (D) region after intradermal application of ALB-Gel and i-PRF; in the left hemiface nasolabial fold (E) region, treated only with i-PRF, no significant change in dermal thickness was observed. The statistical analysis conducted for the Self-Perception Index revealed a  $P < 0.0001$ , indicating a highly significant improvement in participant perception post-treatment. **Conclusion:** The intradermal application of ALB-Gel and i-PRF in a single session significantly increased dermal thickness, indicating this is a simple and low-cost alternative for dermal restructuring.

*Keywords: Platelet-rich fibrin, ageing, rejuvenation, ultrasonography.*

## 1. INTRODUCTION

The skin is the largest organ of the human body, accounting for 16% of body weight; it is responsible for protection, nourishment, and pigmentation, acting as a thermal insulator, offering protection against various environmental agents, and serving sensory functions [1]. The skin is composed of collagen, a protein that provides strength and resilience to this organ. It is produced from precursors - pro-collagen, which are expressed through the coding of genes by dermal fibroblasts [2]. Collagen accounts for approximately 25% to 30% of the total body protein and is responsible for the elasticity and integrity of the skin [3]. As we age, the natural production of collagen decreases, resulting in cutaneous ageing [4].

Skin ageing is a natural process that involves multiple factors (intrinsic and extrinsic). The intrinsic or chronological factor corresponds to the natural wear of cells. In contrast, extrinsic factors include exposure to UV rays, pollution, smoking, alcohol consumption, and lifestyle, with these factors significantly accelerating ageing [5]. In this process, the body undergoes

27 inevitable morphological and physiological changes that manifest molecular changes at the  
28 cellular, histological, and anatomical levels [6].

29 Collagen and elastin are products of fibroblast synthesis that undergo degradation with  
30 excessive exposure to the sun and other extrinsic factors, causing wrinkles and loss of skin  
31 elasticity [7]. The cellular mechanisms of ageing are closely linked to the telomeric  
32 hypothesis observed by Hyflick (1997), that is, with each cell division, chromosomes  
33 undergo changes that prevent proper cell replication [8]. The Hayflick limit explains the fact  
34 that fibroblasts lose part of their telomere with each cell division, which can be used as  
35 biological markers of this process [9].

36 Ageing is characterised by changes in gene expression and increased oxidative stress,  
37 causing DNA anomalies [10,12].

38 Practice in aesthetic medicine offers numerous conventional treatments using materials that  
39 often fail to deliver the results promised by manufacturers [13]. Products produced by  
40 laboratories, no matter how bioidentical they may be, can have immediate and delayed  
41 reactions such as persistent and intermittent late oedema (PLIE) [14,15]. In this context,  
42 platelet concentrate contains a supra-physiological quantity of platelets; these release  
43 growth factors that stimulate tissue repair and skin rejuvenation. Platelet growth factors are  
44 extracellular signalling molecules capable of stimulating a cascade of events such as  
45 fibroblast cell division, cell migration, gene expression (differentiation of mesenchymal cells),  
46 chemotaxis, promotion of angiogenesis, and cell migration [16]. This biomaterial has been  
47 used therapeutically to regulate essential processes in skin rejuvenation [17].

48 Platelet-Rich Plasma (PRP) and Platelet-Rich Fibrin (PRF) are autologous biotherapies used  
49 in Regenerative Aesthetic Medicine. PRP is obtained by centrifuging the patient's blood in  
50 the presence of an anticoagulant to concentrate the platelets, which are rich in growth  
51 factors and are frequently used to promote tissue healing and regeneration. PRF, a second-  
52 generation platelet concentrate, not only concentrates platelets and leukocytes but also  
53 forms a fibrin matrix that allows a slower and more sustained release of growth factors,  
54 providing a prolonged regenerative effect. Both concentrates can serve as a biological basis  
55 for the formation of a gel obtained under the influence of high temperatures. This gel  
56 acquires properties that allow an even slower absorption into the tissue, serving as a more  
57 enduring scaffold to keep the platelets and leukocytes at the desired location and optimise  
58 the delivery of growth factors to the injured tissue. While PRP and PRF focus on the  
59 concentration and delivery of regenerative factors, the gel form adds a structural dimension  
60 to the treatment, potentially enhancing the efficacy of regenerative therapy [44-50].

61 Platelet-Rich Fibrin (PRF), cited by Choukroun (2001) and introduced to the scientific  
62 community by Dohan and Choukroun in a series of articles in 2006, aimed to present a  
63 biological material free of anticoagulants known as healing inhibitors [19,20]. PRF introduced  
64 a new concept for obtaining platelet concentrates without exogenous chemical additives,  
65 becoming a key in tissue engineering by providing three critical factors: cells, growth factors,  
66 and scaffolding [21]. Its role in the healing process has shown efficacy, as cells and growth  
67 factors, crucial in this process, are found in large quantities in the fibrin matrix [20,22]. This  
68 protocol, also known as L-PRF (Leukocyte Platelet-Rich Fibrin), was obtained under high  
69 centrifugal force, characterising fibrin of high density and cellular concentration. Numerous  
70 publications have highlighted the benefits of PRF in the regenerative practice of soft and  
71 hard tissues [23]. New protocols were also established, altering the relative centrifugal force  
72 (RCF) and centrifugation time. In 2014, a new type of PRF obtained at low force, A-PRF  
73 (Advanced Platelet-Rich Fibrin) and A-PRF+, resulted in a more porous fibrin with lower  
74 density and more dispersed cellular settlement [24,25]. In 2015, Mourão and colleagues

75 mentioned in a technical note about i-PRF (Injectable Platelet Rich Fibrin). Still, this protocol  
76 was only well elucidated in subsequent publications by Miron et al. (2017) and Wang et al.  
77 (2018). The use of plastic tubes without activators and additives and modifications in speed  
78 and centrifugation time slowed down the coagulation time [20,26]. The result was a product  
79 containing fibrinogen and thrombin, which remained fluid for about 20 minutes at room  
80 temperature before forming fibrin, making it a suitable injectable material for facial  
81 rejuvenation [27]. Currently, with temperature control, i-PRF in the field of facial aesthetics  
82 allows for an even longer working time [28].

83 In 2018, Mourão et al. discussed a preliminary study on a new technique for obtaining a gel  
84 through the denaturation of albumin present in plasma. In this technique, the platelet-poor  
85 plasma (PPP), mainly containing albumin, is heated for 10 minutes at 75°C, allowing the  
86 denaturation of this material and forming an albumin gel named ALB-Gel [29]. The  
87 denaturation process restructures the proteins into a denser protein structure with extended  
88 resorption properties [29,30]. However, it is already known that, after heat treatment, PRF or  
89 PPP lose their regenerative power, as cells and growth factors are unable to withstand the  
90 denaturation process through heating. Thus, a reintroduction of the buffy coat (platelet-rich  
91 layer) removed from the tube after centrifugation is mixed with ALB-Gel (heated and cooled  
92 PPP), decellularising this biomaterial, then named ALB-PRF [29,31].

93 Volumisation of the soft tissues of the face is one of the most effective procedures for  
94 reducing wrinkles and filling in deeper furrows in some regions of the face, previously  
95 achievable only through surgery [32]. However, despite the advantages of injectable fillers,  
96 their high cost and risks of inflammation from foreign materials to the human body must be  
97 considered [33].

98 Several researchers from different health fields have reported the use of ALB-Gel and i-PRF  
99 in relation to surgical treatments, such as oral, maxillofacial, and aesthetic treatments  
100 [13,30,34–36]. Regarding the use of ALB-Gel and i-PRF in facial rejuvenation and  
101 volumisation, some studies have been emerging in the scientific community; however, there  
102 is still a significant need for research, especially concerning the durability time of this gel  
103 in vivo.

104 With the growing expansion in the field of Aesthetic Medicine, the growth factors contained  
105 within platelet concentrates emerge as a promising therapy, regulating relevant processes in  
106 tissue restructuring and, consequently, in cutaneous rejuvenation. This novel and in vivo  
107 study aims to elucidate the results obtained with the use of ALB-Gel and i-PRF at high  
108 centrifugal force in rejuvenation and volumisation in the nasolabial fold area, utilising a  
109 system that combines objective (skin analysis) and subjective (self-perception questionnaire  
110 and photos) approaches. The effects of applying ALB-Gel and i-PRF separately on the right  
111 hemiface and i-PRF alone on the left hemiface via intradermal route were evaluated to  
112 compare which protocol presents a better result as a volumiser, biostimulator, and  
113 autologous tissue restorer in this region.

## 114 **2 MATERIALS AND METHODS**

115

116 The study was submitted and approved by the Ethics and Research Committee of the  
117 University of Paraíba Valley, Sao Paulo, Brazil (Opinion 5.398.140/CAAE  
118 56591922.5.0000.5503) in accordance with the regulations of the National Health Council by  
119 resolution 466/2012. All participants included in this study were aware of the procedures they  
120 would undergo and signed an Informed Consent Form (ICF).

121 The following inclusion criteria were used: female individuals aged between 35 and 55 years,  
122 with the presence of signs of cutaneous ageing such as sagging, loss of dermal thickness,  
123 and nasolabial folds. Pregnant women, individuals allergic to the components of the pre-  
124 procedure ointment (dermomax), lactating women, individuals with neoplasms, anaemias,  
125 diabetes, deep vein thrombosis, autoimmune diseases, infectious processes, the recent  
126 application of botulinum toxin or fillers, dermatological disease at the site, tanned skins from  
127 sunbathing or artificial tanning, and individuals who had undergone recent surgery (up to 30  
128 days before) and/or use of anti-inflammatory drugs (NSAIDs), antibiotics, and anticoagulants  
129 were excluded.

130 A total of 13 participants were selected for the present study. The participants underwent a  
131 session of application of ALB-Gel and i-PRF separately in the nasolabial fold region on the  
132 right hemiface (ALB-Gel was applied first, followed by i-PRF at the same location and in the  
133 same layer) as the test group. In the nasolabial fold region on the left hemiface, i-PRF was  
134 applied alone as the control group. In both protocols, a 22 G cannula was used for  
135 application in the reticular dermis (deep dermis). After a 21-day interval, the patients  
136 returned for evaluation of the results. For subsequent comparison, the face was  
137 photographed in a frontal position, with right (D) and left (E) profiles.

138 The participants underwent skin ultrasound examinations in the nasolabial fold region, right  
139 hemiface (D), and left hemiface (E), performed by the same examiner, with a 16 MHz linear  
140 transducer (VINNO Technology, Suzhou Co., ltd) to measure dermal thickness, subsequently  
141 analysing the relationship between the initial and final signs for each volunteer.

142 Prior to the commencement of the procedure, the participant was pre-treated with  
143 Dermomax anaesthetic cream for 30 minutes. The protocol began with a venous puncture of  
144 the participant using a 21 G scalp to collect three tubes of 9 ml each, totalling 27 ml of total  
145 blood. The collection was performed in a PET plastic tube, without additives and  
146 anticoagulants, with a sterile white cap from the company (VACUETTE®, Greiner Bio-One).  
147 The collected material was processed in a centrifuge (IntraSpin, Intra-Lock, FL, USA) for 3  
148 minutes at 2700rpm/700g RCF, with the rotor radius to the bottom of the tube (Rmax) being  
149 8.5 cm, according to the protocol previously described (37). After centrifugation, we collected  
150 the area called “the buffy coat”, corresponding to approximately 1.5 ml per centrifuged tube,  
151 totalling a volume of 4.5 ml. The infiltrate was separated with a sterile plastic pipette and  
152 placed in a sterile plastic petri dish, avoiding contact with metal, oxygen, or any instrument  
153 that could trigger the coagulation process. We collected the upper part of the infiltrate, called  
154 platelet-poor plasma (PPP), approximately 1 ml per tube in a 3 ml syringe. We placed the  
155 syringe with PPP in the heater (Thermal Filler, Model BS 92 BPR, BiancoLab, BR) and  
156 subjected it to heating at 75°C for 10 minutes to obtain the gel according to the protocol  
157 described by (31). After cleansing the face with 2% chlorhexidine, we injected 1 ml of i-PRF  
158 in the form of intradermotherapy and 1 ml of ALB-Gel using a 22 G cannula in the retro-  
159 injection technique into the deep dermis (reticular dermis) in the nasolabial fold region of the  
160 right hemiface. We used the same technique on the left hemiface but only injected 1 ml of i-  
161 PRF alone.

162 Participants were instructed to i) not manipulate the application area for at least 12 hours, ii)  
163 avoid exposure to the sun or excessive temperatures for seven days, and iii) avoid using  
164 anti-inflammatory drugs in the seven days following the procedure. Additionally, from the day  
165 after the procedure, further recommendations were: i) use sunscreen with at least SPF 30 on  
166 the application area for 30 days (apply twice a day); ii) not use makeup or cosmetics in the  
167 area for 24 hours; iii) avoid contact with hot water in the first 24 hours after the procedure; iv)  
168 avoid the use of alcoholic beverages for 24 hours; v) avoid the use of acids on the site in the  
169 first 48 hours; and vi) return on the day and time scheduled for their next session.

170 Twenty-one days after treatment, participants underwent a new skin ultrasound examination  
171 to measure whether there was an increase in dermal thickness and quantify this increase in  
172 each right (D) and left (E) hemiface. A paired t-test with a significance level of 5% was used  
173 for this statistical analysis. In addition, new frontal and profile D and E photos were taken  
174 and compared with the initial images. The results were displayed in photographs to allow  
175 evaluation through visual comparison, with records taken before and after the procedure  
176 accompanied by graphs and tables.

177 Participants also answered a subjective self-perception questionnaire with four questions (for  
178 "yes" or "no" responses) regarding the quality of the skin, considering the perception of  
179 improvement in the presence of wrinkles, sagging, expression lines, and hydration after  
180 treatment. To quantify the responses, the Self-Perception Index was created, for which each  
181 response was worth 0 (no) or 1 (yes), so each participant's total score would be between  
182 zero and four. Based on the responses, the occurrence of a significant difference between  
183 the volunteers' scores and the value zero (which would correspond to the absence of any  
184 perceived improvement) was evaluated. For this, the scores on the Self-Perception Index  
185 also underwent statistical evaluation, employing the Wilcoxon test at 5% to verify the  
186 occurrence of significant improvement.

### 187 3 RESULTS

188

189 The thickness of the dermis was measured using 16 MHz ultrasound in the nasolabial fold  
190 regions of the right hemiface (D) and left hemiface (E) before starting the treatment and 21  
191 days after the application of the technique. In Figures 1A, 1B, 2A, 2B, 3A, 3B, 4A, and 4B,  
192 we can observe an increase in the thickness of the superficial dermis, which is hypoechoic (grey),  
193 and the deep dermis, which is echogenic (white).


194

195 Figures 1A and 1B (represent before and after treatment with i-PRF and ALB-Gel). 2A and 2B (express  
196 before and after treatment with i-PRF). The dermis is thicker in Figure (1B), demonstrating a positive  
197 response to the treatment with 1 ml of i-PRF and 1 ml of ALB-Gel.

198




199  
200  
201  
202  
203  
204




Source: The author (2022)

Figures 3A and 3B (represent before and after treatment with i-PRF and ALB-Gel). 4A and 4B (represent before and after treatment with i-PRF). In Figure (3B), the dermis appears to have lost thickness, indicating that other structures must be observed.

205



206  
207  
208



Source: The author (2022)

209 Below, Table 1 presents the results of the measurements and analyses conducted  
210 separately on the right hemiface and the left hemiface.

211  
212  
213

Table 1: Measurements of the nasolabial fold region (values in millimetres) before and after application, right hemiface and left hemiface.

Patient	Right hemiface		Left hemiface	
	Pre-application	Post-application	Pre-application	Post-application
1	2,50	2,11	2,02	2,49
2	2,52	2,48	2,52	2,65

3	1,68	2,64	1,71	2,01
4	1,94	2,20	1,88	2,03
5	2,20	2,42	2,89	2,22
6	2,26	2,97	2,32	2,33
7	2,48	2,64	2,62	2,69
8	2,20	2,44	2,45	2,48
9	2,47	2,96	2,50	2,85
10	2,11	2,48	2,06	2,30
11	2,42	2,76	2,51	2,80
12	1,81	2,00	1,74	1,90
13	2,06	2,34	2,22	2,34
Median	2,20	2,48	2,32	2,34
Mean	2,20	2,50	2,26	2,39
Standard deviation	0,28	0,30	0,36	0,31

Source: The author (2022)

214  
215  
216  
217  
218  
219  
220

For each hemiface, a paired t-test was then applied for statistical analysis, with the initial value being the measurement of dermal thickness before treatment and the final value being the measurement of dermal thickness 21 days after the application of the technique. The paired t-test assumes a normal distribution of values, applying a two-tailed model with statistical significance at  $P < 0.05$ .

221  
222  
223  
224  
225  
226  
227


The paired t-test revealed that for the right hemiface of the nasolabial fold region,  $P < 0.0074$ ; for the left hemiface of the nasolabial fold region,  $P < 0.1259$  was observed. These statistical results indicate a significant increase in dermal thickness in the right hemiface (D) of the nasolabial fold treated with 1 ml of ALB-Gel and 1 ml of i-PRF; on the other hand, the left hemiface (E), treated only with i-PRF, did not show a significant change in dermal thickness (the thickness increase occurs within the margin of error indicated by the standard deviation).

228  
229  
230  
231


Photographic records allowed for the subjective visualisation of the treatment's efficacy on signs of ageing such as wrinkles, sagging, skin vitality, pore changes, and the overall quality of the skin, as seen in figures 5A, 5B patient six and figures 6A, 6B patient 1.

232  
233

Figures 5A, 5B, and 6A, 6B: Pre and Post-application: improvement in the overall appearance of the skin.



234




235  
236

Source: The author (2022)

237 Figures 7 and 8 assist in visualising the obtained results, presenting the box plots for the  
 238 measurements (in millimetres) related to the nasolabial fold, respectively, on the right  
 239 hemiface (Figure 7) and left hemiface (Figure 8). In each of these figures, the diagram of the  
 240 initial measurement is presented on the left and the final measurement on the right, allowing  
 241 for the visualisation of the significant increase in dermal thickness, especially notable in  
 242 Figure 9.

243 Figure 7: Box plots of the epidermal thickness (in millimetres) pertaining to the right hemiface of the  
 244 nasolabial fold. On the left is the initial value; on the right is the final value. The horizontal line within  
 245 the box represents the median, and the "x" marks the mean.



246

247


Source: The author (2022)

248 The treatment on the right hemiface (ALB-Gel followed by i-PRF) results in a clear upward  
 249 shift of the "value box" (boxplot), which is particularly noticeable when observing the internal  
 250 horizontal line (representation of the median), which jumps from 2.2mm (initial right value) to  
 251 about 2.5mm (final right value). Thus, the final box plot has little overlap of values with the  
 252 initial box plot in Figure 7, confirming the significant increase in thickness indicated by the  
 253 paired t-test.

254 In the case of the left hemiface (i-PRF), the upward shift of the box plot is more subtle; in  
 255 particular, the internal horizontal line (representation of the median) remains essentially  
 256 constant, around 2.3mm (Figure 8). Furthermore, there is a significant overlap of values

257 between the initial and final box plots, such that the statistical test cannot indicate a  
258 substantial increase in thickness in this hemiface.

259 Figure 8: Box plots of the epidermal thickness (in millimetres) pertaining to the left hemiface of the  
260 nasolabial fold. On the left is the initial value; on the right is the final value. The horizontal line within  
261 the box represents the median, and the "x" marks the mean.




262

263

Source: The authors (2022)

264 Subsequently, Figure 9 displays the distribution of the Self-Perception Index of improvement  
265 in skin condition based on responses to the applied questionnaire, with scores ranging from  
266 zero to four, where zero indicates "no improvement" and four, "maximum improvement."

267 Figure 9: Self-Perception Index before and after treatment.



268

269

Source: The authors (2022)

270 The self-perception of improvement was quite significant, reaching an average of 3.3 and a  
271 mode of 4 (the maximum possible value).

272 The statistical analysis conducted for the Self-Perception Index resulted in  $P < 0.0001$ ,  
273 proving the participants' perception of effective improvement.

274  
275 **DISCUSSION**

276 The nasolabial fold region represents an essential mark of anti-aesthetic expression  
277 resulting from changes in the pillars of ageing: bone, fat, and dermis. This site is always  
278 requested for therapies traditionally used in Aesthetic Medicine.


279 The most commonly used therapies for this region resort to fillings with hyaluronic acid and  
280 synthetic collagen biostimulators, aiming to increase dermal thickness in this area, improve  
281 the extracellular matrix, and restructure collagen and elastic fibres in general.

282 The effect of platelet concentrates in attracting cells such as fibroblasts to improve the  
283 function of restructuring the dermis is already known. The impact of growth factors in  
284 attracting new vessels and bringing excellent nutrition conditions to the tissues is also well  
285 recognised. With a restructured dermis rich in vessels, platelet concentrates become a  
286 superb therapy. They are natural, low-cost, and easy to apply to restore facial aesthetics  
287 without the use and complications of synthetic materials. In this line of thought, we tested  
288 platelet-rich fibrin in two different forms of application as well as other molecular structures.  
289 The injectable form of PRF, i-PRF, has few tissue-filling characteristics; however, it has a  
290 high biological commitment to stimulating and restoring tissues. On the other hand, albumin  
291 gel has a low potential for cellular biostimulation compared to i-PRF. Still, it has the potential  
292 to be absorbed over a longer time, possibly occupying dermal space and thereby  
293 biostimulating the skin for a more extended period. These two materials can be configured  
294 and mixed to be individualised for different clinical scenarios. Nonetheless, their mixed and  
295 homogenised use, called ALB-PRF, clinically responds with an initial increase in dermal  
296 contour, an expected absorption of the liquid form of PRF in a few days, which has  
297 evidenced an early volumetric loss in our clinical experience. As an application strategy,  
298 aiming to eliminate this initial volumetric loss and count on the stimulus of injectable PRF,  
299 associated with the filling effect of albumin gel (ALB-Gel), we delivered the injectable form  
300 with intradermotherapy done with a 30 G1/2 needle, and subsequent application of the pure  
301 gel done with a 22G cannula. A comparison was made with injectable PRF in a split face.

302 The literature needs to present evidence of the effectiveness of platelet concentrates in gel  
303 form, that is, the biological restructuring and dermal volumising effect. Some South American  
304 countries are prohibited from using traditional hyaluronic acid for facial volumisation. As an  
305 alternative, the use of PRP in the form of "plasma gel dermal filler" found in the literature is  
306 also infrequent. Anitua et al. presented two works on this subject on biological  
307 characterisation, dermal thickening, and clinical results only in 2018, already showing good  
308 outcomes with evident dermal thickening.

309 There are already some cases in the literature of necrosis and vascular occlusion likely  
310 caused by PRP in gel form in glabellar regions [38]. Despite the liquid form of the  
311 concentrates being entirely safe, the use of gel forms, whether PRP or PRF, requires proper  
312 technique and care and should be applied in anatomically and aesthetically safe areas since  
313 no substance degrades the gel, unlike hyaluronidase for hyaluronic acid. In Figure 10, we  
314 can observe the risk area.

315 Figure 10: Zone of complications requiring caution during applications.



316

317 Source: Adapted from the book " *Complicações na estética corporal e facial e o uso da*  
 318 *ultrassonografia* "(43)

319 For the viability of application in this technique, we used a high-force centrifugation protocol  
 320 to have well-separated cellularised and acellular areas in a single blood sample, as Mayron  
 321 showed in his work. The portion near the red area is cellularised (buffy coat). It has excellent  
 322 biological potential, as it is rich in platelets and leukocytes and is used for the composition of  
 323 injectable PRF. In the same tube, the upper part contains an acellular sample, which will be  
 324 heated to obtain ALB-Gel. This heating causes cell death and denatures molecular  
 325 elements. Therefore, it is necessary to use the most acellular portion possible to avoid  
 326 injecting these cellular remnants into the tissue, which may have some inflammatory  
 327 potential. Low-force protocols keep the entire volume of centrifuged blood highly cellularised,  
 328 making it impossible to separate these areas from obtaining PRF-GEL, contraindicating its  
 329 use for this technique. Although it is evident that the exclusion of dead cells from the  
 330 concentrate should be done, further studies must be conducted to verify this inflammatory  
 331 potential.

332 The evidence obtained in this study with the application of different forms of PRF proves that  
 333 platelets, fibrin, leukocytes, and growth factors, along with another acellular biological  
 334 material like PRF GEL, seem to have a significant meaning in maintaining volume and  
 335 attracting fibroblasts for dermal restructuring. It is worth mentioning that this restructuring is  
 336 validated by the high growth factors in i-PRF, including vascular endothelial growth factor  
 337 (VEGF), which ensures this restructuring through angiogenesis [21,39–41].

338 The literature has shown that platelet concentrates should be applied at least twice to  
 339 achieve the best results, with an interval of no less than 21 days [42]. In a study by Brodt et  
 340 al., dermal thickness enhancement is observed following the initial application and further  
 341 increases after the second application. In this study, the first application was performed to  
 342 prove dermal improvement. Other studies should be conducted already employing the

343 technique of applying i-PRF and ALB-Gel concentrates separately to demonstrate progress  
344 in different areas and to define the interval between them.

345 There were no significant incidents or side effects, only minor oedema and bruises, which  
346 disappeared within a week after application. The use of anaesthesia in the infraorbital nerve  
347 ensured a painless procedure.

348 The negative data measured in the present work can be attributed to the influence of  
349 working conditions with the ultrasound equipment. The pressure that the professional applies  
350 on the transducer over the skin can influence the results and the difference in the thickness  
351 of the contact gel between the transducer and the skin. A minimal amount of gel interferes  
352 with the clarity of the ultrasonographic image, making it challenging to measure dermal  
353 thickness. It is important to emphasise the importance of prior training of a single  
354 professional in this work to measure the dermis in order to establish a standard for this  
355 study. Although no study specifies the adequate thickness of contact gel between the  
356 transducer and skin to evaluate images appropriately, it was observed that an increased gel  
357 thickness provides better image resolution. And this is confirmed among most ultrasound  
358 professionals.

359 Upon reviewing the figures (graphs and photos), it is noted that the outcomes of the  
360 examination were satisfactory. Nonetheless, the clarity of the visual result in the photo  
361 examination appeared less pronounced, as evidenced by the images of Figure 5A and 5B  
362 for patient six in Table 1. This indicates the necessity to consider other underlying structures  
363 for analysis, including subcutaneous and muscular layers, regional inflammation, and the  
364 skin type of the treated area.

365 Despite treatment with i-PRF via intradermotherapy appearing to be the best treatment  
366 route, its results are sometimes questioned due to the lack of a methodological standard and  
367 the absence of comparative studies. However, its clinical outcomes in routine practice  
368 encourage further studies to support its effectiveness in facial aesthetics as a treatment and  
369 in the preparation of the local biological terrain.

370

## 371 **CONCLUSION**

372 In this novel and in vivo study, it is possible to conclude that the protocol of i-PRF with high  
373 centrifugal force provides satisfactory dermal thickening results and the subjective aesthetic  
374 response of the individuals studied in the nasolabial fold region. The comparison between  
375 the gains obtained on the right and left hemiface suggests that the separate application of  
376 ALB-Gel enhances the treatment with i-PRF, increasing the results' significance. Despite the  
377 need for further studies of this material, this approach indicates a fundamental direction for  
378 more assertive clinical guidance in treatments with platelet concentrates aimed at  
379 volumising, biostimulation, and autologous tissue regeneration.

## 380 **ACKNOWLEDGEMENTS**

381  
382  
383 The research presented herein was a collective endeavour undertaken by all contributing  
384 authors. We sincerely thank Biancolab company for their generous donation of materials  
385 essential for conducting this study.  
386

387 **COMPETING INTERESTS**

388

389 The authors declare that there are no conflicts of interest.

390

391 **AUTHORS' CONTRIBUTIONS**

392

393 RPG initiated and designed the research, developed the project framework, engaged in the  
394 gathering of data, and played a pivotal role in the manuscript preparation. FPB also initiated  
395 and designed the study, was instrumental in data acquisition, and made substantial  
396 contributions to the manuscript's composition. CMDM was involved in the data collection  
397 process. PRB and ACOCD were integral to conducting the study's statistical analyses.  
398 GRDF and MFC, in collaboration with theco-authors, meticulously reviewed and edited the  
399 manuscript, ensuring their approval of the final version. JCP offered invaluable oversight and  
400 guidance throughout the research process.

401

402 **CONSENT**

403

404 Every participant in this study was fully briefed on the procedures they were to undergo and  
405 provided their signed Informed Consent Form (ICF). Documentation of these consent forms  
406 is accessible for examination by the Editorial Office, Chief Editor, or members of the Editorial  
407 Board of this journal.

408

409 **ETHICAL APPROVAL**

410

411 The authors collectively affirm that all experiments conducted in this study underwent  
412 scrutiny and authorisation by the pertinent ethics committee, thus ensuring adherence to the  
413 ethical guidelines delineated in the 1964 Declaration of Helsinki.

414

415 **REFERENCES**

416

417 1. MOORE, K. L; DARLLY AF. Anatomia orientada para a clínica. 4. Rio de Janeiro:  
418 Guanabara; 2001.

419 2. Poon F, Kang S, Chien AL. Mechanisms and treatments of photoaging. Photodermatol  
420 Photoimmunol Photomed [Internet]. 2015 Mar;31(2):65–74. Available from:  
421 <https://onlinelibrary.wiley.com/doi/10.1111/phpp.12145>

422 3. Visnardi AR. Efeito do ultra-som de baixa intensidade no colágeno da pele sadia de ratos  
423 [Internet]. [São Carlos]: Universidade de São Paulo; 2007. Available from:  
424 <http://www.teses.usp.br/teses/disponiveis/82/82131/tde-14022008-105151/>

425 4. Anunciato TP. Nutricosméticos [Internet]. [Ribeirão Preto]: Universidade de São Paulo;  
426 2011. Available from: <http://www.teses.usp.br/teses/disponiveis/60/60137/tde-20092011-210914/>

428 5. Ortolan MCAB, Biondo-Simões M de LP, Baroni E do RV, Auersvald A, Auersvald LA,  
429 Montemor Netto MR, et al. Influência do envelhecimento na qualidade da pele de mulheres  
430 brancas: o papel do colágeno, da densidade de material elástico e da vascularização. Rev  
431 Bras Cir Plástica [Internet]. 2013 Mar;28(1):41–8. Available from:  
432 [http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S1983-51752013000100008&lng=pt&nrm=iso&tlng=en](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1983-51752013000100008&lng=pt&nrm=iso&tlng=en)  
433

- 434 6. I EJMR, Yadira D, Corrales M. Bioestimulación facial con plasma rico en plaquetas. Arch  
435 Médico Camagüey. 2015;19(2):167–78.
- 436 7. Sataloff RT, Johns MM, Kost KM. Envelhecimento cutâneo: Teoria dos radicais livres e  
437 tratamentos visando a preservação e o rejuvenescimento. Rev Uningá. 2010;24.
- 438 8. Gava AA, Zanoni JN. Envelhecimento Celular. Arq Ciências da Saúde da UNIPAR  
439 [Internet]. 2005;9(1):41–6. Available from: <http://revistas.unipar.br/saude/article/view/218/192>
- 440 9. Naveilhan P, Baudet C, Jabbour W, Wion D. A theory that may explain the Hayflick limit  
441 — a means to delete one copy of a repeating sequence during each cell cycle in certain  
442 human cells such as fibroblasts. Mech Ageing Dev [Internet]. 1994 Sep;75(3):205–13.  
443 Available from: <https://linkinghub.elsevier.com/retrieve/pii/0047637494900108>
- 444 10. Borson LAMG, Romano LH. Revisão: O processo genético de envelhecimento e os  
445 caminhos para a longevidade. Rev Saúde em Foco – Edição no 12 – Ano 2020 [Internet].  
446 2020;239–44. Available from: [https://portal.unisepe.com.br/unifia/wp-](https://portal.unisepe.com.br/unifia/wp-content/uploads/sites/10001/2020/08/REVISÃO-O-PROCESSO-GENÉTICO-DE-ENVELHECIMENTO-E-OS-CAMINHOS-PARA-A-LONGEVIDADE-239-a-244.pdf)  
447 [content/uploads/sites/10001/2020/08/REVISÃO-O-PROCESSO-GENÉTICO-DE-](https://portal.unisepe.com.br/unifia/wp-content/uploads/sites/10001/2020/08/REVISÃO-O-PROCESSO-GENÉTICO-DE-ENVELHECIMENTO-E-OS-CAMINHOS-PARA-A-LONGEVIDADE-239-a-244.pdf)  
448 [ENVELHECIMENTO-E-OS-CAMINHOS-PARA-A-LONGEVIDADE-239-a-244.pdf](https://portal.unisepe.com.br/unifia/wp-content/uploads/sites/10001/2020/08/REVISÃO-O-PROCESSO-GENÉTICO-DE-ENVELHECIMENTO-E-OS-CAMINHOS-PARA-A-LONGEVIDADE-239-a-244.pdf)
- 449 11. Castelo-Branco C. Envejecimiento de la piel y las mucosas. Madrid, Espanha; 2010.
- 450 12. Silva WJM da, Ferrari CKB. Metabolismo mitocondrial, radicais livres e envelhecimento.  
451 Rev Bras Geriatr e Gerontol [Internet]. 2011;14(3):441–51. Available from:  
452 [http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S1809-](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1809-98232011000300005&lng=pt&tlng=pt)  
453 [98232011000300005&lng=pt&tlng=pt](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1809-98232011000300005&lng=pt&tlng=pt)
- 454 13. Nacopoulos C. Uso da Fibrina Rica em Plaquetas na Estética e no Rejuvenescimento  
455 Facial. In: Fibrina rica em plaquetas na odontologia regenerativa e estética: bases biológicas  
456 e aplicações clínicas. 2018th ed. São Paulo: Quintessence Editora; 2018. p. 215–35.
- 457 14. Breda PL de CL. Edema Tardio Intermitente Persistente (ETIP), após uso de  
458 substâncias a base de ácido hialurônico / Persistent Delayed Intermittent Edema (ETIP)  
459 after using hyaluronic acid-based substances. Brazilian J Heal Rev [Internet]. 2022 Jul  
460 15;5(4):12821–38. Available from:  
461 <https://brazilianjournals.com/ojs/index.php/BJHR/article/view/50317>
- 462 15. Cavallieri FA, Balassiano LK de A, Bastos JT de, Fontoura GHM da, Almeida AT de.  
463 Persistent, Intermittent Delayed Swelling PIDS intermitent swelling: late adverse reaction to  
464 Hyaluronic Acid fillers. Surg Cosmet Dermatology [Internet]. 2017;9(3). Available from:  
465 <http://www.surgicalcosmetic.org.br/detalhe-artigo/583>
- 466 16. Takamori ER, Teixeira MVT, Menezes K, Carias RBV, Borojevic R. Fibrina rica em  
467 plaquetas: preparo, definição da qualidade, uso clínico. Vigilância Sanitária em Debate.  
468 2018;6(1):118.
- 469 17. Hassan H, Quinlan DJ, Ghanem A. Injectable platelet-rich fibrin for facial rejuvenation: A  
470 prospective, single-center study. J Cosmet Dermatol [Internet]. 2020 Dec 23 ;19(12):3213–  
471 21. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/jocd.13692>
- 472 18. Choukroun J. Une opportunité en paro-implantologie : le PRF. Implantodontie.  
473 2001;42(55):e62.

- 474 19. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJJ, Mouhyi J, et al. Platelet-rich  
475 fibrin (PRF): A second-generation platelet concentrate. Part I: Technological concepts and  
476 evolution. *Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology* [Internet]. 2006  
477 Mar;101(3):e37–44. Available from:  
478 <https://linkinghub.elsevier.com/retrieve/pii/S107921040500586X>
- 479 20. Miron RJ, Fujioka-Kobayashi M, Hernandez M, Kandalam U, Zhang Y, Ghanaati S, et al.  
480 Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry? *Clin Oral*  
481 *Investig* [Internet]. 2017 Nov 2;21(8):2619–27. Available from:  
482 <http://link.springer.com/10.1007/s00784-017-2063-9>
- 483 21. Fujioka-Kobayashi M, Miron RJ. Biological Components of Platelet Rich Fibrin: Growth  
484 Factor Release and Cellular Activity. In: *Platelet Rich Fibrin in Regenerative Dentistry:*  
485 *Biological Background and Clinical Indications* [Internet]. Oxford, UK: John Wiley & Sons,  
486 Ltd; 2017. p. 15–31. Available from:  
487 <https://onlinelibrary.wiley.com/doi/10.1002/9781119406792.ch2>
- 488 22. Miron RJ, Choukroun J. *Fibrina rica em plaquetas na odontologia e medicina*  
489 *regenerativa e estética: bases biológicas e aplicações clínicas*. 2018th ed. São Paulo:  
490 Quintessence Editora; 2018.
- 491 23. Cortellini S, Castro AB, Temmerman A, Van Dessel J, Pinto N, Jacobs R, et al.  
492 Leucocyte- and platelet-rich fibrin block for bone augmentation procedure: A proof-of-  
493 concept study. *J Clin Periodontol* [Internet]. 2018 May;45(5):624–34. Available from:  
494 <https://onlinelibrary.wiley.com/doi/10.1111/jcpe.12877>
- 495 24. Ghanaati S, Booms P, Orlowska A, Kubesch A, Lorenz J, Rutkowski J, et al. Advanced  
496 Platelet-Rich Fibrin: A New Concept for Cell-Based Tissue Engineering by Means of  
497 Inflammatory Cells. *J Oral Implantol* [Internet]. 2014 Dec 1;40(6):679–89. Available from:  
498 [https://meridian.allenpress.com/joi/article/40/6/679/6702/Advanced-PlateletRich-Fibrin-A-](https://meridian.allenpress.com/joi/article/40/6/679/6702/Advanced-PlateletRich-Fibrin-A-New-Concept-for)  
499 [New-Concept-for](https://meridian.allenpress.com/joi/article/40/6/679/6702/Advanced-PlateletRich-Fibrin-A-New-Concept-for)
- 500 25. El Bagdadi K, Kubesch A, Yu X, Al-Maawi S, Orlowska A, Dias A, et al. Reduction of  
501 relative centrifugal forces increases growth factor release within solid platelet-rich-fibrin  
502 (PRF)-based matrices: a proof of concept of LSCC (low speed centrifugation concept). *Eur J*  
503 *Trauma Emerg Surg* [Internet]. 2019 Jun 21 ;45(3) :467–79. Available from:  
504 <http://link.springer.com/10.1007/s00068-017-0785-7>
- 505 26. Wang X, Zhang Y, Choukroun J, Ghanaati S, Miron RJ. Effects of an injectable platelet-  
506 rich fibrin on osteoblast behavior and bone tissue formation in comparison to platelet-rich  
507 plasma. *Platelets* [Internet]. 2018 Jan 2;29(1):48–55. Available from:  
508 <https://www.tandfonline.com/doi/full/10.1080/09537104.2017.1293807>
- 509 27. Wang X, Yang Y, Zhang Y, Miron RJ. Fluid platelet-rich fibrin stimulates greater dermal  
510 skin fibroblast cell migration, proliferation, and collagen synthesis when compared to  
511 platelet-rich plasma. *J Cosmet Dermatol* [Internet]. 2019 Dec 16;18(6):2004–10. Available  
512 from: <https://onlinelibrary.wiley.com/doi/10.1111/jocd.12955>
- 513 28. Miron RJ, Horrocks NA, Zhang Y, Horrocks G, Pikos MA, Sculean A. Extending the  
514 working properties of liquid platelet-rich fibrin using chemically modified PET tubes and the  
515 Bio-Cool device. *Clin Oral Investig* [Internet]. 2022 Mar 23;26(3):2873–8. Available from:  
516 <https://link.springer.com/10.1007/s00784-021-04268-x>

- 517 29. Barros Mourão C de A, Gheno E, Lourenço E, Barbosa RL, Kurtzman G, Javid K, et al.  
518 Characterization of a new membrane from concentrated growth factors associated with  
519 denaturized Albumin (Alb-CGF) for clinical applications: A preliminary study. *Int J Growth*  
520 *Factors Stem Cells Dent* [Internet]. 2018;1(2):64. Available from:  
521 <http://www.cellsindentistry.org/text.asp?2018/1/2/64/235911>
- 522 30. Doghaim NN, El-Tatawy RA, Neinaa YME. Assessment of the efficacy and safety of  
523 platelet poor plasma gel as autologous dermal filler for facial rejuvenation. *J Cosmet*  
524 *Dermatol* [Internet]. 2019 Oct 26;18(5):1271–9. Available from:  
525 <https://onlinelibrary.wiley.com/doi/10.1111/jocd.12876>
- 526 31. Fujioka-Kobayashi M, Schaller B, Mourão CFDAB, Zhang Y, Sculean A, Miron RJ.  
527 Biological characterization of an injectable platelet-rich fibrin mixture consisting of  
528 autologous albumin gel and liquid platelet-rich fibrin (Alb-PRF). *Platelets* [Internet].  
529 2021;32(1):74–81. Available from: <https://doi.org/10.1080/09537104.2020.1717455>
- 530 32. Carruthers J, Cohen SR, Joseph JH, Narins RS, Rubin M. The science and art of dermal  
531 fillers for soft-tissue augmentation. *J Drugs Dermatol* [Internet]. 2009 Apr;8(4):335–50.  
532 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19363852>
- 533 33. Requena L, Requena C, Christensen L, Zimmermann US, Kutzner H, Cerroni L. Adverse  
534 reactions to injectable soft tissue fillers. *J Am Acad Dermatol* [Internet]. 2011 Jan;64(1):1–  
535 34. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0190962210006973>
- 536 34. İzol BS, Üner DD. A New Approach for Root Surface Biomodification Using Injectable  
537 Platelet-Rich Fibrin (I-PRF). *Med Sci Monit* [Internet]. 2019 Jun 26; 25:4744–50. Available  
538 from: <https://www.medscimonit.com/abstract/index/idArt/915142>
- 539 35. Ozsagir ZB, Saglam E, Sen Yilmaz B, Choukroun J, Tunali M. Injectable platelet-rich  
540 fibrin and microneedling for gingival augmentation in thin periodontal phenotype: A  
541 randomized controlled clinical trial. *J Clin Periodontol* [Internet]. 2020 Apr;47(4):489–99.  
542 Available from: <https://onlinelibrary.wiley.com/doi/10.1111/jcpe.13247>
- 543 36. Janmey PA, Winer JP, Weisel JW. Fibrin gels and their clinical and bioengineering  
544 applications. *J R Soc Interface* [Internet]. 2009 Jan 6;6(30):1–10. Available from:  
545 <https://royalsocietypublishing.org/doi/10.1098/rsif.2008.0327>
- 546 37. Cortellini S, Castro AB, Temmerman A, Van Dessel J, Pinto N, Jacobs R, et al.  
547 Leucocyte- and platelet-rich fibrin block for bone augmentation procedure: A proof-of-  
548 concept study. *J Clin Periodontol*. 2018;45(5):624–34.
- 549 38. Karam EZ, Gan A, Muci Mendoza R, Martinez E, Perez E. Visual Loss after Platelet-rich  
550 Plasma Injection into the Face. *Neuro-Ophthalmology* [Internet]. 2020 Nov 1;44(6):371–8.  
551 Available from: <https://www.tandfonline.com/doi/full/10.1080/01658107.2020.1740936>
- 552 39. Antônio Colussi da Silva J, Giacomini M, Warmeling M, Miranda Pagnoncelli R. Uso do  
553 hormônio do crescimento associado à fibrina rica em plaquetas e leucócitos injetável (I-  
554 PRF). *Rev da Fac Odontol - UPF*. 2019;24(2):309–15.
- 555 40. Rodríguez Flores J, Palomar Gallego MA, Torres García-Denche J. Plasma rico en  
556 plaquetas: fundamentos biológicos y aplicaciones en cirugía maxilofacial y estética facial.  
557 *Rev Española Cirugía Oral y Maxilofac* [Internet]. 2012 Jan;34(1):8–17. Available from:  
558 <https://linkinghub.elsevier.com/retrieve/pii/S113005581100102X>

- 559 41. Choi SW, Pangeni R, Jung DH, Kim SJ, Park JW. Construction and Characterization of  
560 Cell-Penetrating Peptide-Fused Fibroblast Growth Factor and Vascular Endothelial Growth  
561 Factor for an Enhanced Percutaneous Delivery System. *J Nanosci Nanotechnol* [Internet].  
562 2018 Feb 1 ;18(2) :842–7. Available from:  
563 <http://www.ingentaconnect.com/content/10.1166/jnn.2018.14864>
- 564 42. Brodt FP, Garcia RP, Costa MF, Marchi CM De, Barja PR, Doria ACOC, et al. Evaluation  
565 of Injectable Platelet-rich Fibrin (i-PRF) as an Autologous Tissue Regenerator in Facial  
566 Aesthetics. *J Adv Med Med Res* [Internet]. 2023 Sep 13;35(21):97–109. Available from:  
567 <https://journaljamr.com/index.php/JAMMR/article/view/5215>
- 568 43. Donola, Gisele, and Vivian Castilho. *Complicações Na Estética Corporal e Facial e o*  
569 *Uso Da Ultrassonografia*. 1st ed., vol. 1, Napoleão Quintessence Publishing Brazil, 2023.
- 570 44. Napit IB, Shrestha D, Neupane K, et al, Autologous blood products: Leucocyte and  
571 Platelets Rich Fibrin (L-PRF) and Platelets Rich Plasma (PRP) gel to promote cutaneous  
572 ulcer healing – a systematic review *BMJ Open* 2023;13: e073209. doi: 10.1136/bmjopen-  
573 2023-073209
- 574 45. Dhurat R, Sharma A, Goren A, Daruwalla S, Situm M, Kovacevic M. Mission impossible:  
575 Dermal delivery of growth factors via microneedling. *Dermatol Ther* [Internet]. 2019 May  
576 22;32(3). Available from: <https://onlinelibrary.wiley.com/doi/10.1111/dth.12897>
- 577 46. Tovar N, Benalcázar Jalkh EB, Ramalho IS, Rodriguez Colon R, Kim H, Bonfante EA, et  
578 al. Effects of relative centrifugation force on <scp>L-PRF</scp>: An in vivo submandibular  
579 boney defect regeneration study. *J Biomed Mater Res Part B Appl Biomater* [Internet]. 2021  
580 Dec 3;109(12):2237–45. Available from:  
581 <https://onlinelibrary.wiley.com/doi/10.1002/jbm.b.34885>
- 582 47. Xue, Xin et al. "Evaluation of injectable platelet-rich fibrin produced by a simple twice-  
583 centrifugation method combined with vacuum sealing drainage technology in the treatment  
584 of chronic refractory wounds." *Frontiers in bioengineering and biotechnology* vol. 10 979834.  
585 28 Oct. 2022, doi:10.3389/fbioe.2022.979834
- 586 48. Mahmoodabadi, Razieh Ahmadi et al. "Evaluation of the Effect of Platelet-Rich Fibrin  
587 Matrix in the Correction of Periorbital Wrinkles: An Experimental Clinical Trial." *Dermatology*  
588 *practical & conceptual* vol. 13,1 e2023050. 1 Jan. 2023, doi:10.5826/dpc.1301a50
- 589 49. Dashore, Shuken et al. "Platelet-Rich Fibrin, Preparation and Use in Dermatology."  
590 *Indian Dermatology Online Journal* vol. 12, Suppl 1 S55-S65. 25 Nov. 2021,  
591 doi:10.4103/idoj.idoj\_282\_21
- 592 50. Lidia Majewska, "Platelet-Rich Fibrin as an Effective Method of Skin Revitalization",  
593 *Dermatologic Therapy*, vol. 2023, Article ID 9040608, 4 pages, 2023.  
594 <https://doi.org/10.1155/2023/9040608>